Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583288 | 1.00 | DCPS (0.64) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8628496 | 0.83 | CLK1 (0.54) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3487308 | 0.82 | KDM4E (0.50) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12733670 | 0.82 | CLK1 (0.66) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1675370 | 0.82 | CLK1 (0.66) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31061156 | 0.82 | CLK1 (0.66) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8630481 | 0.81 | MDM4 (0.47) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL840416 | 0.80 | CLK1 (0.51) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12733642 | 0.80 | CLK1 (0.51) | DCPSKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL71734 | 0.80 | CLK1 (0.51) | DCPSKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273637-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Institut National de la Santé et de la Recherche Médicale (FR) | 2022-09-01 | — | — | US | claimed |
| EP-3996697-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Université de Bretagne Occidentale (U.B.O.) (FR) | 2022-05-18 | — | — | EP | claimed |
| WO-2021005189-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | UNIVERSITE DE BRETAGNE OCCIDENTALE (UBO) (FR) | 2021-01-14 | — | — | WO | claimed |
| US-12421537-B2 | Ribosome variants for sequence defined polymer synthesis | NORTHWESTERN UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025113647-A3 | PHENANTHRIDIN-6-AMINES FOR USE IN THE TREATMENT OF CANCERS EXPRESSING EBV ANTIGENS | SCIENTIAM PHARMA (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025113647-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OR THE PREVENTION OF EBV-ASSOCIATED DISORDERS | SCIENTIAM PHARMA (FR) | 2025-06-05 | — | — | WO | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240382602-A1 | A CIS-PLATINUM(II)-OLIGOMER HYBRID | DUBLIN CITY UNIVERSITY (IE) | 2024-11-21 | — | — | US | disclosed |
| CN-118103385-A | Cis-platinum (II) oligomer hybrids | 都柏林城市大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| WO-2007060342-A2 | USE OF GUANABENZ AND ITS DERIVATIVES FOR MAKING DRUGS FOR TREATING CYSTIC FIBROSIS AND DISEASES RELATED TO A PROTEIN ADDRESSING DEFICIENCY IN THE CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-05-31 | — | — | WO | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1551992-B1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NAT RECH SCIENT (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1551992-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035813-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-29 | — | — | WO | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | DCPS 271/4885KDM4E 3590/4885ALDH1A1 72/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | DCPS 2702/4885KDM4E 2700/4885ALDH1A1 2586/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | DCPS 271/4885KDM4E 3590/4885ALDH1A1 72/4885 |
| US-20240382602-A1 | A CIS-PLATINUM(II)-OLIGOMER HYBRID | PCNA, DCLRE1A, LIG4 | DCPS 378/4885KDM4E 4861/4885ALDH1A1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.